Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

J Julio Rosenstock (Velocity Clinical Research Center at Medical City Dallas, Dallas) S Stanley Hsia (Velocity Clinical Research, Huntington Park, CA) L Luis Nevarez Ruiz (Hospital Angeles Chihuahua, Chihuahua, Mexico) S Sarah Eyde (Eli Lilly, Indianapolis) D David Cox (Eli Lilly, Indianapolis) W Wen-Shuo Wu (Eli Lilly, Indianapolis) R Rong Liu (School of Materials Science and Engineering) J Jianghao Li (Eli Lilly, Indianapolis) L Laura Fernández Landó (Eli Lilly, Indianapolis) M Max Denning (Eli Lilly, Indianapolis) L Lisa Ludwig (Eli Lilly, Indianapolis) Y Yanyun Chen (Eli Lilly, Indianapolis)

Article Details

Volume / Issue Vol. 393, Issue 11
Published September 18, 2025
Pages 1065-1076
ISSN 0028-4793
Publisher Massachusetts Medical Society

Journal Info

New England Journal of Medicine

Massachusetts Medical Society

ISSN: 0028-4793 Social Sciences

Authors (12)

J

Julio Rosenstock

Velocity Clinical Research Center at Medical City Dallas, Dallas

S

Stanley Hsia

Velocity Clinical Research, Huntington Park, CA

L

Luis Nevarez Ruiz

Hospital Angeles Chihuahua, Chihuahua, Mexico

S

Sarah Eyde

Eli Lilly, Indianapolis

D

David Cox

Eli Lilly, Indianapolis

W

Wen-Shuo Wu

Eli Lilly, Indianapolis

R

Rong Liu

School of Materials Science and Engineering

J

Jianghao Li

Eli Lilly, Indianapolis

L

Laura Fernández Landó

Eli Lilly, Indianapolis

M

Max Denning

Eli Lilly, Indianapolis

L

Lisa Ludwig

Eli Lilly, Indianapolis

Y

Yanyun Chen

Eli Lilly, Indianapolis